Atlas Trials

Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia

Clinical trial NCT04349306 · COMPLETED

Trial details

NCT number
NCT04349306
Sponsor
Sanofi
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Lymphoma
Start date
2020-05-14
Primary completion
2021-03-12
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.